+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
FEMALE
ID07604766

Comparing Rina-S and Investigators Choice Chemotherapy for Platinum-Resistant Ovarian Cancer in China

Led by Genmab · Updated on 2026-11-03

82

Participants Needed

17

Research Sites

65 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how well a drug called Rina-S works compared to standard chemotherapy treatments for women with platinum-resistant ovarian cancer in China. This Phase 3 study focuses on patients who have ovarian, primary peritoneal, or fallopian tube cancer that does not respond well to platinum-based chemotherapy. The study aims to compare Rina-S against chemotherapy drugs already approved and used for this condition, providing important data on treatment options for this difficult-to-treat cancer. Participants will receive either Rina-S or one of four approved chemotherapy drugs Paclitaxel, Topotecan, Pegylated liposomal doxorubicin PLD, or Gemcitabine. Treatments are given through intravenous infusions. Participants have an equal chance of receiving Rina-S or the investigators choice of chemotherapy. The study does not include any placebo treatments and is an extension of a previous study. Treatment will continue as assigned, and researchers will monitor participants closely. During the trial, participants will undergo regular assessments to monitor cancer progression and treatment effects, including scans and laboratory tests. Researchers will track progression-free survival up to about 16 months and other outcomes like overall survival, response rates, quality of life, and adverse events for up to approximately 25 months. The study involves ongoing monitoring to understand the impact of treatments over time, with participation lasting up to nearly three years from the start date.

CONDITIONS

Brief Title

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

Research Team

G

Genmab Trial Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here